Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in tumor samples from younger patients with neuroblastoma.
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: mutation analysis
Genetic: protein analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Proposed Studies on the Role of Growth Factor Receptor Trafficking in Neuroblastoma Pathogenesis|
- Expression of UBE4B, hrs, and members of the ubiquitination protein complex [ Designated as safety issue: No ]
- Expression levels and cellular localization of the UBE4B, hrs, and growth factor receptors [ Designated as safety issue: No ]
- 1p36 deletion status and its association with UBE4B [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||December 2011|
|Primary Completion Date:||July 2016 (Final data collection date for primary outcome measure)|
- To determine the expression of UBE4B, hrs, and members of the ubiquitination protein complex in previously banked primary neuroblastoma tumor samples from the Children's Oncology Group.
- To determine the correlation of expression levels and cellular localization of the UBE4B and hrs proteins with growth factor-receptor tumor cell-surface expression.
- To determine the 1p36 deletion status by fluorescence in situ hybridization (FISH) analysis and their association with expression levels of UBE4B and hrs in previously banked primary neuroblastoma tumor samples from the Children's Oncology Group.
OUTLINE: Banked tumor tissue samples are analyzed for expression of UBE4B, hrs, members of the ubiquitination protein complex, growth factor receptors, and 1p36 deletion status by immunohistochemistry (IHC), fluorescent microscopy, and fluorescence in situ hybridization (FISH).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01493830
|Principal Investigator:||Peter Zage, MD, PhD||Texas Children's Cancer Center|